1,705 reports of this reaction
1.7% of all MIRABEGRON reports
#9 most reported adverse reaction
NAUSEA is the #9 most commonly reported adverse reaction for MIRABEGRON, manufactured by Astellas Pharma US, Inc.. There are 1,705 FDA adverse event reports linking MIRABEGRON to NAUSEA. This represents approximately 1.7% of all 99,871 adverse event reports for this drug.
MIRABEGRON has an overall safety score of 78 out of 100. Patients taking MIRABEGRON who experience nausea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
NAUSEA is a less commonly reported adverse event for MIRABEGRON, but still significant enough to appear in the safety profile.
In addition to nausea, the following adverse reactions have been reported for MIRABEGRON:
The following drugs have also been linked to nausea in FDA adverse event reports:
NAUSEA has been reported as an adverse event in 1,705 FDA reports for MIRABEGRON. This does not prove causation, but indicates an association observed in post-market surveillance data.
NAUSEA accounts for approximately 1.7% of all adverse event reports for MIRABEGRON, making it a notable side effect.
If you experience nausea while taking MIRABEGRON, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.